Singapore, Nov. 13 -- US-basedBostonGene, developer of the leading AI foundation model for cancer and the immune system, andKyoto University, a Japanese research institution known for its groundbreaking advancements in medicine and science, have announced a research collaboration to develop advanced biological signatures to enhance targeted treatment strategies for patients with esophageal squamous cell carcinoma (ESCC).

This research will leverage BostonGene's AI-powered, multi-scale, omnimodal platform to analyse tumour molecular profiles and assess their correlation with response to a novel immune checkpoint inhibitor (ICI) and chemoradiotherapy (CRT) combination therapy.

The study builds on the NOBEL trial, an investigator-initiated...